Clinuvel has announced it will start treatment of vitiligo patients with its drug afamelanotide under a new study protocol (CUV104).
Latest Video
New Stories
-
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News

